Neogenomics Laboratories, Inc.
Fort Myers, FL
- UEI
- ML9LFC5CK7K9
- CAGE
- 1ADC5, 67VT1
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Neogenomics Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 9490 Neogenomics Wy, Fort Myers, FL 33912, USA
- Website
- neogenomics.com
- Founded
- 2002
- Employees
- 1K-5K
- Estimated annual revenue
- $500M-$1B
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health Care Services
- SIC code
- 80 Health Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $2,797,350 |
| FY2026 | $2,439,957 |
| FY2025 | $1,955,673 |
| FY2024 | $2,715,709 |
| FY2023 | $3,855,863 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $5,237,307 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Exact Sciences Laboratories, LLC | Madison, WI | 621511 Medical Laboratories |
| Foundation Medicine, Inc. | Boston, MA | 621511 Medical Laboratories |
| Veracyte, Inc. | South San Francisco, CA | 621511 Medical Laboratories |
| Mayo Clinic Laboratories | Rochester, MN | 621511 Medical Laboratories |
| Boca Biolistics, LLC | Pompano Beach, FL | 238990 All Other Specialty Trade Contractors |
About the company
Neogenomics Laboratories, Inc., headquartered in Fort Myers, Florida, is a for-profit cancer diagnostics laboratory that delivers specialized reference laboratory testing services to the federal government as a prime contractor across 115 awards with no subcontractor involvement. The company competes exclusively in full-and-open procurements—no set-aside designations appear across its federal footprint—and operates entirely as a prime, with no recorded sub-awards.
Neogenomics' federal capability set centers on advanced diagnostic and reference laboratory testing: human genomics testing, anatomic pathology analysis, genetic sequencing, flow cytometry, cytogenetic analysis, immunohistochemistry, fluorescence in situ hybridization (FISH) testing, and diagnostic testing for hematological disorders and malignancies. Representative work includes a $16 million indefinite-delivery contract with VA Veterans Integrated Service Network 17 for specialized reference laboratory testing (NAICS 621511, Medical Laboratories) supporting multiple VA medical centers with performance in Miromar Lakes, Florida and San Antonio, Texas; a $5 million IDC with VA VISN 21 for oncology and molecular laboratory testing services with a $643,694 delivery order issued April 26, 2026; a $3.076 million BPA with VA VISN 1 for FISH testing services with a $500,000 call issued April 1, 2026; and a $2.125 million BPA with Indian Health Service for lab diagnostic testing issued June 1, 2026.
Customer concentration reflects VA and Indian Health Service dominance. The top five customer organizations account for 55% of award count. By potential value, the top five account for 82% of combined potential value, led by VA VISN 17 (10 awards, $23.7 million), VA VISN 21 (10 awards, $13.8 million), VA VISN 1 (13 awards, $7.3 million), Indian Health Service (16 awards, $6.5 million), and VA VISN 4 (8 awards, $6.1 million). The vendor has worked with 19 distinct federal agencies across the past five years, with secondary exposure to the National Heart Lung and Blood Institute and Defense Health Agency; a $445,942 definitive contract with Defense Health Agency for anatomic pathology services at David Grant Medical Center, Travis Air Force Base, runs September 1, 2024 through August 31, 2027.
Neogenomics holds five named parent vehicles: a $16 million IDC with VA VISN 17 (7 task orders totaling $3.2 million), a $5 million IDC with VA VISN 21 (6 task orders totaling $1.4 million), a $3.076 million BPA with VA VISN 1 (5 task orders totaling $4.9 million), a $2.125 million BPA with Indian Health Service (8 task orders totaling $497 thousand), and a $659,350.80 BPA with VA VISN 19 (6 task orders totaling $328 thousand). The VISN 17 and VISN 21 vehicles alone represent over $4.2 million in issued delivery orders through fiscal 2026.
Activity has remained stable with 8–14 awards per year over the past five years (2022: 10 awards, 2023: 8 awards, 2024: 14 awards, 2025: 8 awards, 2026: 8 awards to date). Seven awards with combined potential value of $5 million reach ultimate completion within the next twenty-four months, representing moderate recompete exposure concentrated in VISN contracts.
SCI-reportable invoiced revenue totals $3.2 million across FY2023–FY2024. The vendor reported $1.4 million in FY2023 across 0.5 FTEs and $1.8 million in FY2024 across 1.4 FTEs, with zero FTEs recorded in FY2022 and FY2025. SCI data captures only federal service contracts above the $150,000 threshold and excludes goods and product-based revenue; the majority of Neogenomics' federal work consists of testing services, which do not consistently trigger SCI reporting thresholds. On federal service contracts captured in SCI, government-paid rates ran median around $950/hr, with senior labor pricing through $2,270/hr and junior labor as low as $590/hr. Across SCI-reportable prime contracts, the vendor performed 100% of contractor hours in-house with no named subcontractor engagement, reflecting a fully captive delivery model.
Quick answers
Is Neogenomics Laboratories, Inc. registered in SAM.gov?
Yes. Neogenomics Laboratories, Inc.'s SAM.gov registration is active through March 24, 2027.
How much has Neogenomics Laboratories, Inc. received in federal contracts?
Federal contracts obligated $1,955,673 to Neogenomics Laboratories, Inc. in fiscal year 2025 and $13,764,551 in fiscal years 2023 through 2027.
How does Neogenomics Laboratories, Inc. rank among federal contractors?
Neogenomics Laboratories, Inc.'s parent company, Neogenomics Inc., ranked #23 in NAICS 621511, #31 in NAICS 6215 and #40 in PSC Q3 in FY2025.
What is Neogenomics Laboratories, Inc.'s most recent federal award?
Neogenomics Laboratories, Inc.'s most recent federal contract award is STX specialized reference laboratory testing (36C25727N0090), from Veterans Integrated Service Network 17 (VHA), on January 1, 2027.
On GovTribe
See Neogenomics Laboratories, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors